CX3CL1 and Parkinson disease: The existing evidence does not allow for definite conclusions regarding the role of fractalkine in PD pathophysiology, but our results suggest an anti-inflammatory effect with lower levels being associated with PD-FOG and with PD-NoFOG compared to HC.